Drug Shortage Report for TARO-DOXORUBICIN LIPOSOMAL
Report ID | 237366 |
Drug Identification Number | 02493020 |
Brand name | TARO-DOXORUBICIN LIPOSOMAL |
Common or Proper name | Doxorubicin |
Company Name | TARO PHARMACEUTICALS INC |
Market Status | MARKETED |
Active Ingredient(s) | DOXORUBICIN HYDROCHLORIDE |
Strength(s) | 2MG |
Dosage form(s) | SUSPENSION |
Route of administration | INTRAVENOUS |
Packaging size | 10mL Vial |
ATC code | L01DB |
ATC description | CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2024-09-12 |
Estimated end date | 2024-12-31 |
Actual end date | 2024-10-15 |
Shortage status | Resolved |
Updated date | 2024-10-31 |
Company comments | US-authorized inventory will be available for shortage mitigation |
Health Canada comments | |
Tier 3 Status | Yes |
Contact Address | 130 EAST DRIVE BRAMPTON, ONTARIO CANADA L6T 1C1 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v14 | 2024-10-31 | French | Compare |
v13 | 2024-10-31 | English | Compare |
v12 | 2024-10-07 | French | Compare |
v11 | 2024-10-07 | English | Compare |
v10 | 2024-10-07 | French | Compare |
v9 | 2024-10-07 | English | Compare |
v8 | 2024-10-04 | French | Compare |
v7 | 2024-10-04 | English | Compare |
v6 | 2024-09-25 | English | Compare |
v5 | 2024-09-19 | French | Compare |
v4 | 2024-09-19 | English | Compare |
v3 | 2024-09-13 | English | Compare |
v2 | 2024-09-12 | French | Compare |
v1 | 2024-09-12 | English | Compare |
Showing 1 to 14 of 14